Hemlibra and Koate-DVI

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using emicizumab together with antihemophilic factor may increase the risk of blood clots, which can lead to serious complications such as stroke, pulmonary embolism (blockage of pulmonary artery), heart attack, heart failure, collapse, and kidney failure. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you experience potential signs and symptoms of blood clots such as chest pain; shortness of breath; coughing up blood; blood in the urine; sudden loss of vision; and pain, redness, or swelling in your arm or leg. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Preclinical experiments suggest a possibility for hypercoagulability when emicizumab is used with factor VIIa or factor VIII.

MANAGEMENT: Patients should be monitored for development of thrombosis if emicizumab is coadministered with factors VIIa or VIII.

Hemlibra

Generic Name: emicizumab

Brand name: Hemlibra, Hemlibra 105 mg/07 mL, Hemlibra 60 mg/04 mL

Synonyms: n.a.

What is Hemlibra?

Koate-DVI

Generic Name: antihemophilic factor

Brand name: Hemofil-M, Koate-DVI, Monoclate-P, Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Jivi, Obizur

Synonyms: Koate-DVI (human)

What is Koate-DVI?